Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Jul 12;13(7):e0200532.
doi: 10.1371/journal.pone.0200532. eCollection 2018.

Participant perspectives of a home-based palliative approach for people with severe multiple sclerosis: A qualitative study

Ambra Mara Giovannetti  1   2 , Claudia Borreani  3 , Elisabetta Bianchi  3 , Andrea Giordano  1 , Sabina Cilia  4 , Susanna Cipollari  5 , Ilaria Rossi  5 , Claudia Cavallaro  4 , Valentina Torri Clerici  2 , Edoardo Rossetti  2 , Maria Consiglia Stefanelli  6 , Amadio Totis  2 , Angelo Pappalardo  4 , Gina Occhipinti  4 , Paolo Confalonieri  2 , Simone Veronese  7 , Maria Grazia Grasso  5 , Francesco Patti  4 , Paola Zaratin  8 , Mario Alberto Battaglia  9 , Alessandra Solari  1 ; PeNSAMI project
Affiliations
Randomized Controlled Trial

Participant perspectives of a home-based palliative approach for people with severe multiple sclerosis: A qualitative study

Ambra Mara Giovannetti et al. PLoS One. .

Abstract

Background: We performed a qualitative study to investigate the experiences of participants in a multicentre randomized controlled trial on a home-based palliative approach (HPA) for adults with severe multiple sclerosis (MS) and their caregivers. Our aim was to explore the strengths and challenges of the intervention, and circumstances that may have influenced its efficacy.

Methods: Participants to the qualitative study were the patients, their caregivers, patient referring physicians, and the teams who delivered the HPA intervention. We performed semi-structured one-on-one interviews with 12 patients and 15 informal caregivers chosen using a maximum variation strategy, two focus group meetings with patient referring physicians (4 participants each), and one with the HPA teams (9 participants).

Results: From data analysis (framework method) 38 sub-categories emerged, which were grouped into 10 categories and 3 themes: 'expectations,' 'met and unmet needs', and 'barriers'. Intervention benefits were improved control of symptoms and reduced sense of isolation of the patient-caregiver dyads. Limitations were: factors related to experimental design (difficulty of dyads in identifying examiner and team roles, additional burden for caregivers); team issues (insufficient team building /supervision, competing priorities); limitations of the intervention itself (insufficient length, lack of rehabilitation input); and external factors (resource limitations, under-responsive services/professionals). The referring physician focus groups provided little experiential data.

Conclusions: The HPA reduced patient symptoms and sense of isolation in patients and caregivers. The indirect role of the HPA teams, and insufficient length of the intervention were key limitations. The experimental design imposed additional burdens on the dyads. Key barriers were the paucity of available services, the demanding administrative procedures, and lack of networking facilities. These findings suggest that two major requirements are necessary for home palliative care to be effective in this patient population: HPA teams well-connected with MS rehabilitation services, and care delivered over the long-term, with variable intensity.

Trial registration: Current Controlled Trials ISRCTN73082124 (Registered 19/06/2014).

PubMed Disclaimer

Conflict of interest statement

FP has received speaking honoraria from, and has been a board member of: Alimirall, Bayer, Biogen, Celgene, Merck, Novartis, Roche, Sanofi Genzyme, and Teva. VTC has been a board member of Merck, Novartis, Sanofi Genzyme. She has received travel expenses from Almirall, Biogen, Merck; speaking/writing honoraria from Almirall, Merck, and Teva; and support from Almirall for a research project. AS has been a board member of Biogen, Merck, and Novartis; she has received speaker honoraria from Almirall, Excemed, Merck, Sanofi Genzyme, and Teva. The authors confirm that this declaration does not alter the authors’ adherence to all PLOS ONE policies on sharing data and materials.

References

    1. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain. 2006;129: 584–594. 10.1093/brain/awh721 - DOI - PubMed
    1. Gruenewald DA, Higginson IJ, Vivat B, Edmonds P, Burman RE. Quality of life measures for the palliative care of people severely affected by multiple sclerosis: a systematic review. Mult Scler. 2004;10: 690–704. 10.1191/1352458504ms1116rr - DOI - PubMed
    1. Higginson IJ, Hart S, Silber E, Burman R, Edmonds P. Symptom prevalence and severity in people severely affected by multiple sclerosis. J Palliat Care. 2006;22: 158–165. - PubMed
    1. Giordano A, Ferrari G, Radice D, Randi G, Bisanti L, Solari A, on behalf of the POSMOS study. Self-assessed health status changes in a community cohort of people with multiple sclerosis: 11 years of follow-up. Eur J Neurol. 2013; 20(4): 681–588. 10.1111/ene.12028 - DOI - PubMed
    1. Campbell CW, Jones EJ, Merrills J. Palliative and end-of-life care in advanced Parkinson's disease and multiple sclerosis. Clin Med. 2010;10(3): 290–292. - PMC - PubMed

Publication types

Associated data